Beckman Coulter has released new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide. The rapid, high-quality assays run on Beckman Coulter’s scalable AU clinical chemistry analysers and shorten turnaround time for patient test results to hours instead of days – leading to more successful managing and
monitoring of treatments of patients.
In a new agreement with Saladax Biomedical, Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as Schizophrenia and Bipolar Disorder. These new assays are developed using an innovative nanoparticle technology and empower healthcare professionals with data to monitor psychiatric drugs prescribed in treatment of psychosis: Clozapine, Risperidone/ Paliperidone, Olanzapine, Quetiapine, Aripiprazole. Kathleen Orland, senior vice president and general manager, clinical chemistry and immunoassay, Beckman Coulter, commented: “Beckman Coulter’s portfolio of therapeutic drug monitoring assays offers laboratories and diagnostic testing facilities ways to improve patient care by ensuring therapeutic ranges are monitored. Our relationship with Saladax expands access for laboratories and clinicians to antipsychotic drug testing for treatment of psychotic disorders, which is a growing healthcare need.”
The new assays are being introduced across Europe and the US, with plans to expand to Beckman Coulter customers globally.
For more information, visit: www.beckmancoulter.com/antipsychotic
Digital issue: Please click here for more information